College+of+Life+Science+and+Bioengineering
-
Professor Joonho Choe Appointed as the President of the KSMCB
Professor Joonho Choe of the Biological Sciences Department at KAIST has been elected the 25th president of Korean Society for Molecular and Cellular Biology (KSMCB).
His presidency will last one year, beginning on January 1, 2016.
Established in 1989, the Society has served as the largest academic gathering in the field of life sciences, holding an international conference every fall. It has more than 12,400 fellows.
Professor Choe served as the vice president of KSMC as well as the editor of its journal, Molecules and Cells.
He said, “The 2016 International Conference of the KSMCB will take place on October 12-14, 2016 at the COEX Convention and Exhibition Hall in Seoul. This year, we are preparing 20 symposiums and will invite four international renowned keynote speakers in the field including a Nobel Laureate. We hope many people, students and young researchers in particular, from academia and industry will join the conference.”
Professor Choe received his doctoral degree from the University of California, Los Angeles (UCLA) after graduating from Seoul National University with his bachelor and master’s degrees.
2016.01.05 View 6944 -
Professor Jeong Ho Lee Receives the 2015 Pediatric Epilepsies Research Award
The award identifies leading scientists worldwide and funds their cutting-edge research in epilepsy.
The Citizen United for Research in Epilepsy (CURE) announced on September 7, 2015, that Jeong Ho Lee, a professor of the Graduate School of Medical Science and Engineering at KAIST, will be awarded the 2015 Pediatric Epilepsies Research Award.
The Pediatric Epilepsies Research Award is given annually to a researcher who has conducted novel, innovative research projects that address severe, intractable pediatric epilepsies as well as collaborative, interdisciplinary projects that explore new approaches to find a treatment for pediatric epilepsies.
Lee was recognized for his leading study in the field of intractable epilepsy. He is the first Korean who has ever received this award, securing a research grant of USD 250,000 for two years.
Lee has conducted research on brain somatic mutations as the novel cause of childhood intractable epilepsy. Pediatric epilepsies account for approximately 70% of all cases of epilepsy.
Established in 1998, CURE is a non-profit American organization based in Chicago, Illinois, which is committed to funding research and various initiatives that will lead to breakthroughs to cure epilepsy.
Since its inception, CURE has been at the forefront of epilepsy research, raising more than USD 32 million to support researchers and scientists worldwide. It has also awarded more than 180 cutting-edge projects in 13 countries.
2015.09.09 View 10175 -
The Journal of Clinical Investigation: Researchers Uncover the Secret Lymphatic Identity of the Schlemm's Canal
The Journal of Clinical Investigation (JCI), a peer-reviewed, top-tier medical journal published by the American Society for Clinical Investigation, carried a commentary entitled “Schlemm’s Canal: More Than Meets the Eye, Lymphatics in Disguise” in the July 25, 2014 issue.
In the commentary, the authors compared a research paper (“Lymphatic regular PROX1 determines Schlemm’s canal integrity and identity”) by Professor Gou-Young Koh of the Graduate School of Medical Science and Engineering at KAIST with research work from the University of Helsinki (article entitled “The Schlemm’s canal is a VEGF-C/VEGFR-3 responsive lymphatic-like vessel”).
The JCI released a press statement dated July 25, 2014 on its commentary. It mentioned that glaucoma, one of the leading causes of blindness worldwide, elevates eye pressure owing to poor drainage of aqueous humor. A specialized structure called “Schlemm’s canal” funnels aqueous humor from the eye back into circulation, which is critical to prevent pressure buildup in the eye. The article discussed the role of Schlemm’s canal in the context of lymphatic vascular characteristics by reviewing two research group’s papers back-to-back.
For the full text of the press release, please visit the link below:
Press Release from the Journal of Clinical Investigation, July 25, 2014
“Researchers uncover the secret lymphatic identity of the Schlemm’s canal”
http://www.eurekalert.org/pub_releases/2014-07/joci-rut072414.php
2014.07.28 View 7604 -
Seo-Eun Lee, an undergaruate student receives the Best Paper Award from Optical Society of Korea
Seo-Eun Lee, a student studying at KAIST’s Department of Biological Sciences, has won the Best Paper Award from Bio-Photonics Division at the 2014 Optical Society of Korea Winter Conference, held on 19th February at Daejeon Convention Center.
Only one outstanding paper per division is given an award among the total of 270 papers, and it is very unusual for an undergraduate student to win the award in the field that is not her major.
Lee has studied cell imaging using holography technology since June 2013 under the supervision of Professor Yong-Geun Park from the Department of Physics.
The Optical Society of Korea was founded in 1989, and as the largest academy in the field of optics in Korea, it holds academic presentations, seminars and lectures every year.
2014.03.06 View 9066 -
Professor Kim Eun Joon receives In Chon Award
Professor Kim Eun Joon (Department of Biological Sciences) received the In Chon Awarded hosted by In Chon Memorial and Dong Ah Newspaper.
The Award Ceremony will be held on the 8th of October in Seoul Lotte Hotel and Professor Kim will be given a medal and prize money amounting 100million Korean Won.
Professor Kim is a world renowned research in the field of Synapses. Professor Kim graduated from the Department of Pharmacy in Pusan University, B.A. at KAIST, and Ph.D at Michigan University. He has been a Professor at KAIST since 2000.
2012.09.11 View 7750 -
KAIST Prof. Park Selected as Winner of Clemson Award
Professor Tae-Gwan Park of the Department of Biological Sciences, KAIST, was chosen as the winner of the 2009 Clemson Award for Fundamental Research, university authorities said on Tuesday (April 7).
The award is the highest recognition of the Society for Biomaterials, an international organization of more than 3,000 members that promotes research in the field of biomaterials. Prof. Park is cited for his outstanding achievements in interdisciplinary research covering gene transferring, gene therapy and neogenesis. It is rare for a non-U.S. national to win the prize in the 36-year history of the award.
The award will be given to Professor Park at the Annual Meeting of the society which will be held in San Antonio, Texas, on April 22.
2009.04.09 View 11597 -
Prof. Chung Named Winner of 2008 KAIST Scientific Award
Professor Chung Jong-Kyeong of the Department of Biological Sciences was named the winner of the 2008 KAIST Scientific Award.
The prize was awarded by KAIST President Suh Nam-Pyo during the 37th KAIST anniversary ceremony on Feb. 16.
Chung was cited for disclosing the new anti-cancer aspect of adenosine monophosphate-activated protein kinase (AMPK). His papers, published in the science magazine Nature in 2006 and again in 2007, revealed that the protein could be used to treat certain forms of cancer, as well as prevent malignant growths.
2008.02.28 View 12123 -
Professor Eunjoon Kim's team finds synapse-forming protein
Professor Eunjoon Kim’s team finds synapse-forming protein
- discover a new protein ‘NGL’ that promotes the formation of neuronal synapses
- can presume the cause of various brain disorders including schizophrenia
- will be published at Nature Neuroscience Vol. 9 in September
A new protein that promotes the formation of synapses in human brains was discovered by a Korean research team.
The team led by Eunjoon Kim, Professor of Department of Biological Sciences and Head of Creative Research Group of Synapse Formation), announced that it had discovered a new fact that NGL protein promotes the formation of neuronal synapses and this fact would be published in Nature Neuroscience Vol. 9 on September 18.
Professor Kim’s team discovered that a membrane protein named ‘NGL’ located at post synapse links with other membrane protein named netrin-G in pre synapse, acting as crosslink, and promotes the formation of a new synapse.
‘NGL’ is the second protein found to crosslink synapse, following neuoroligin. With the discovery of this new protein, the principle of synapse formation and the causes of various brain disorders can be presumed.
In the human brain, about more than 100 billion neuron cells and about 10,000 synapses compose neural circuit. A synapse is the place where innervation occurs between neuron cells. The formation of synapse induces the formation of neural circuit, and neural circuit is deeply related with various brain disorders as well as normal development of brains or brain functions.
“As netrin-G linked with NGL is related with schizonphrenia and neuoroligin and synapse crosslinking protein having a similar function with NGL is deeply related with mental retardation and autism, I think NGL is related with various brain disorders including schizophrenia.”
<Explanation of attached photos>
■ Photo1: Experiment for confirming NGL’s ability to form synapse No. 1
Mix ordinary cell (green) revealing NGL at its surface and neuron cell. Axon grows toward NGL (ordinary cell) located in the middle of ten o’clock direction and meets NGL, where NGL induces the formation of pre synapse (red) in the contacting axon.
Whether pre synapse has been formed can be told by the fluorescent dying (red) of pre synapse protein named Synapsin.
- Figure a-b: formation of synapse by NGL
- Figure c-d: transformed NGL losing synapse forming ability cannot form synapse
■ Photo 2: Experiment for confirming NGL’s ability to form synapse No. 2
When beads coated with NGL are scattered on neuron cell, the beads contact with the axon of the neuron cell (the beads are clearly visible at the phase differentiation image in the middle panel). At this time, NGL induces the formation of pre synapse (red) in the axon. Whether pre synapse has been formed can be told by the fluorescent dying (red) of pre synapse protein named SynPhy (panel a) or VGlut1 (panel b).
2006.09.21 View 14607
-
Professor Tae-Gwan Park awarded Minister Prize
Professor Tae-Gwan Park awarded Minister Prize
Professor Tae-Gwan Park (Department of Biological Sciences) was awarded the Minister Prize in the science innovation sector at the NANO KOREA 2006, which was opened on August 30.
This prize is given to researchers who have shown excellent research results in the field of Nanotechnology, and Professor Park was awarded the Minister Prize in recognition of his innovative achievements in the fields of Tissue Engineering, Drug Delivery, Gene Therapy, which are fusion technologies of NT and BT that utilize nanobiomaterials.
2006.09.06 View 13929
-
Gene Protecting Brain Nerves Discovered
THE KOREA TIMES 2005.1.31By Kim Tae-gyu / Staff Reporter
South Korean scientists have for the first time discovered genes tasked with protecting brain nerves.
Korea Advanced Institute of Science and Technology professor Kim Jae-seob said Sunday the new genes, named pyrexia, shield brain nerves from outside stimuli, including high temperatures.
``The channel gene of pyrexia will open the door to developing new-concept medicines for brain damage in patients of high fever or drug addicts,’’ he said.
The channel gene refers to transport proteins, which provide a static passageway for a variety of essential substances to enter into cells.
``Up until now, a lot of channel genes activated by temperatures have been identified. But among them, pyrexia is first that guards brain nerves from external stresses,’’ Kim said.
Kim’s team learned pyrexia plays a pivotal role in the body through experiments with genetically engineered flies that did not have any pyrexia.
Up to 60 percent of the pyrexia-depleted mutants were paralyzed within three minutes of exposure to a temperature of 40 degrees Celsius.
In comparison, just 9 percent of normal flies were paralyzed with the same stimulus, indicating pyrexia is responsible for protecting animals from high-temperature stress.
``Our next goal is to develop pyrexia-embedded drugs, which can be expected to commercially debut in about five years,’’ Kim said.
Kim has already applied for international patents for his medical breakthrough, which will be printed in the March edition of Nature Genetics, a science journal.
voc200@koreatimes.co.kr
2005.02.02 View 13843
-
Nerve-protecting gene discovered
Korean scientists for the first time have identified a gene that blocks nerve damage from fevers and the use of narcotics, a state-run research institute said yesterday.
The finding may open the way for new medicine that can prevent the loss of brain function which is frequently caused by excessive stimulation of nerves and abnormally high body temperature.
"The research is in an early stage. But this approach has the potential to develop genetics-based preventatives against brain-attacking diseases," said Kim Jae-seob, a bioscience professor of the Korea Advanced Institute of Science and Technology, who led the study.
The researchers named the gene Pyrexia, which means fever. Kim"s team extracted it from genetically engineered fruit flies using a genome-screening system. In laboratory tests, they found that the gene is activated to 39 degrees Celsius or higher.
The researchers enhanced Pyrexia"s functionality in some fruit flies while removing the gene from others to observe their different reactions when exposed to high temperature.
"The fruit flies without the gene showed severe nerve disorder and suffered paralysis of brain function, while Pyrexia-enhanced flies maintained their normal brain conditions," the professor said.
The researchers got the same result from experiments with human cells, he said.
There are a lot of channel proteins, which enable ions to enter and exit the cell, that react to the level of temperature, but Pyrexia is the first of its kind that actually protects the neurons from external stimulus, he said.
The finding will appear on the March edition of the London-based science magazine Nature Genetics.
THE KOREA HERALD 2005.1.31 (thkim@heraldm.com) By Kim Tong-hyung
2005.02.02 View 13680
-
Researchers Find Mechanism of Tumor Suppressor Genes
By Kim Tae-gyu. Staff ReporterTHE Korea Times 02-06-2004
Korean scientists continue to break new ground in fighting cancer as domestic researchers examined the mechanism of a gene which can help detect and treat various sorts of cancer.
Korea Advanced Institute of Science and Technology (KAIST) Prof. Lim Dae-sik on Thursday said his team uncovered the mechanism of RASSF1A (Ras Association Domain Family 1 A), or tumor suppressor genes, for the first time in the world.
The gene was widely considered to play an important role in reducing the proliferation of cancer cells, but its exact function and processes have remained unknown up to now.
It is the second cancer-related breakthrough by Koreans in a week after Korea Institute of Science and Technology (KIST) Prof. Chung Hesson unveiled the oral anti-cancer drug.
``Cancer results from the failed management of cell cycles due to things like radiation. After a two-year intensive study, we found out how RASSF1A governs the cell cycle,"" Lim said.
Lim added cancer is caused by abnormal cells, which continue to grow and divide out of control unlike normal cells, which die over time. Cancer cells develop into malignant tumors, eventually inflicting damaging effect on the human body.
As a result, a lack of the RASSF1A indicates a high possibility of cancer and injection of it into cells is believed to help cure the deadly disease, according to Lim.
Dr. Song Min-sup, who took charge of the research, said the findings will especially pave the way for the detection and treatment of lung cancer.
``The dearth of RASSF1A was reported mostly in the case of lung cancer. The new findings will provide insight into the diagnosis and cure of lung cancer from its early stages,"" Song explained.
Lung cancer is a very elusive disease because it doesn"t cause symptoms in its infancy. When symptoms do occur, usually it is too late.
``We expect commercial detection kits or drugs for lung cancer in around five years after pre-clinic experimentation and two-phase clinic trials,"" Song expected.
Details of the study is available in the scientific journal Nature Cell Biology in its February edition.
voc200@koreatimes.co.kr
2004.03.15 View 16229